These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 16573347)

  • 1. The future of antisense oligonucleotides in the treatment of respiratory diseases.
    Ulanova M; Schreiber AD; Befus AD
    BioDrugs; 2006; 20(1):1-11. PubMed ID: 16573347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of antisense oligonucleotide and siRNA-based therapeutics.
    Chi X; Gatti P; Papoian T
    Drug Discov Today; 2017 May; 22(5):823-833. PubMed ID: 28159625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense molecules for targeted cancer therapy.
    Wacheck V; Zangemeister-Wittke U
    Crit Rev Oncol Hematol; 2006 Jul; 59(1):65-73. PubMed ID: 16750913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Respirable antisense oligonucleotides: a new, third drug class targeting respiratory disease.
    Nyce J
    Curr Opin Allergy Clin Immunol; 2002 Dec; 2(6):533-6. PubMed ID: 14752337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oligonucleotide Therapy for Obstructive and Restrictive Respiratory Diseases.
    Liao W; Dong J; Peh HY; Tan LH; Lim KS; Li L; Wong WF
    Molecules; 2017 Jan; 22(1):. PubMed ID: 28106744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense oligonucleotides for the treatment of dyslipidaemia.
    Visser ME; Witztum JL; Stroes ES; Kastelein JJ
    Eur Heart J; 2012 Jun; 33(12):1451-8. PubMed ID: 22634577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disarmed anthrax toxin delivers antisense oligonucleotides and siRNA with high efficiency and low toxicity.
    Dyer PDR; Shepherd TR; Gollings AS; Shorter SA; Gorringe-Pattrick MAM; Tang CK; Cattoz BN; Baillie L; Griffiths PC; Richardson SCW
    J Control Release; 2015 Dec; 220(Pt A):316-328. PubMed ID: 26546271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics.
    Ramasamy T; Ruttala HB; Munusamy S; Chakraborty N; Kim JO
    J Control Release; 2022 Dec; 352():861-878. PubMed ID: 36397636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense DNA and RNA agents against picornaviruses.
    Lim T; Yuan J; Zhang HM; Sall A; Liu Z; Su Y; Yang D
    Front Biosci; 2008 May; 13():4707-25. PubMed ID: 18508540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo reduction of hepatitis B virus antigenemia and viremia by antisense oligonucleotides.
    Billioud G; Kruse RL; Carrillo M; Whitten-Bauer C; Gao D; Kim A; Chen L; McCaleb ML; Crosby JR; Hamatake R; Hong Z; Garaigorta U; Swayze E; Bissig KD; Wieland S
    J Hepatol; 2016 Apr; 64(4):781-9. PubMed ID: 26658683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recent progress and prospect in oligonucleotide therapeutics].
    Yoshioka K; Kuwahara H; Nishina K; Nagata T; Yokota T
    Nihon Rinsho; 2015 Jun; 73(6):1057-65. PubMed ID: 26065142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The promise, pitfalls and progress of RNA-interference-based antiviral therapy for respiratory viruses.
    DeVincenzo JP
    Antivir Ther; 2012; 17(1 Pt B):213-25. PubMed ID: 22311654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Making sense of antisense.
    Vidal L; Blagden S; Attard G; de Bono J
    Eur J Cancer; 2005 Dec; 41(18):2812-8. PubMed ID: 16289851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amphoteric liposomes enable systemic antigen-presenting cell-directed delivery of CD40 antisense and are therapeutically effective in experimental arthritis.
    Andreakos E; Rauchhaus U; Stavropoulos A; Endert G; Wendisch V; Benahmed AS; Giaglis S; Karras J; Lee S; Gaus H; Bennett CF; Williams RO; Sideras P; Panzner S
    Arthritis Rheum; 2009 Apr; 60(4):994-1005. PubMed ID: 19333921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PEG-modification on the endo-position of an antisense oligonucleotide increases tumor accumulation via the EPR effect.
    Hagiwara K; Kurihara K; Honma M; Yamamoto J; Shinohara F
    J Biomater Sci Polym Ed; 2018 Mar; 29(4):448-459. PubMed ID: 29318941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense oligonucleotides as therapeutic agents.
    Alama A; Barbieri F; Cagnoli M; Schettini G
    Pharmacol Res; 1997 Sep; 36(3):171-8. PubMed ID: 9367660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver as a target for oligonucleotide therapeutics.
    Sehgal A; Vaishnaw A; Fitzgerald K
    J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic applications of antisense oligonucleotides in asthma and allergy.
    Isidoro-García M; Dávila I
    Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):171-5. PubMed ID: 19075979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense oligonucleotide-based therapeutics for cancer.
    Dean NM; Bennett CF
    Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.
    Sardone V; Zhou H; Muntoni F; Ferlini A; Falzarano MS
    Molecules; 2017 Apr; 22(4):. PubMed ID: 28379182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.